Hope Rugo, MD

Dr Rugo on Challenges Faced as a Woman in Oncology

March 11th 2024

Hope S. Rugo, MD, discusses challenges that women face in the workplace in oncology care.

Dr Rugo on the Evolution of ADCs in HR+/HER2+ and HER2-Low Breast Cancer

March 9th 2024

Hope Rugo, MD, discusses the evolution of antibody-drug conjugates in hormone receptor–positive, HER2-positive, and HER2-low breast cancer.

Dr. Rugo on HER2 Differentiation in Metastatic Breast Cancer

November 9th 2022

Hope Rugo, MD, discusses the challenges of differentiating between HER2-low and HER2-negative metastatic breast cancer and prognostic differences in HER2+ and HER2-low metastatic breast cancer.

Dr. Rugo on the Benefit of Margetuximab Plus Chemotherapy in HER2+ Metastatic Breast Cancer

March 6th 2021

Hope S. Rugo, MD, discusses the benefit of margetuximab-cmkb in patients with HER2-positive breast cancer who have received prior HER2-targeted therapies.

Dr. Rugo on the Significance of Becoming a Giant in Cancer Care

December 3rd 2020

Hope S. Rugo, MD, discusses the significance of becoming a Giant of Cancer Care®.

Dr. Rugo on the Optimal Setting for Biosimilar Evaluation

November 20th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the optimal setting for biosimilar evaluation.

Dr. Rugo on Resistance to CDK4/6 Inhibitors in HR+ Breast Cancer

November 14th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses resistance to CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

Dr. Rugo Discusses the Equivalency of Trastuzumab Biosimilars

November 3rd 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the equivalency that has been demonstrated with biosimilars for trastuzumab (Herceptin).

Dr. Rugo Discusses a Comparative Review of Trastuzumab Biosimilars

October 27th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses a comparative review of trastuzumab (Herceptin) biosimilars.

Dr. Rugo on Pathway Blockade in Breast Cancer

October 10th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses pathway blockade in breast cancer.

Dr. Rugo Discusses Advancements With Biosimilars

March 2nd 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses recent advancements with biosimilars.

Dr. Rugo on Ongoing Trials in HER2+ Breast Cancer

February 7th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses ongoing trials for patients with HER2-positive breast cancer.

Dr. Rugo Discusses Immunotherapy in TNBC

November 15th 2017

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses immunotherapy in triple-negative breast cancer.

Dr. Rugo Discusses Late Recurrence in HR+ Breast Cancer

October 31st 2017

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses late recurrence in patients with hormone receptor (HR)-positive breast cancer.

Dr. Hope Rugo on Safety of Trastuzumab Biosimilar for HER2+ Breast Cancer

October 14th 2016

Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses MYL-1401O, a proposed biosimilar for trastuzumab (Herceptin), in patients with HER2-positive metastatic breast cancer.

Dr. Hope Rugo on Trastuzumab Biosimilar in HER2-Positive Breast Cancer

August 24th 2016